FDA Approves REXTOVY — International Medication Systems, Ltd.

International Medication Systems, Ltd. received FDA approval for its nasally administered naloxone hydrochloride (Rextovy, NDA208969) on March 7, 2023, potentially expanding the company’s foothold in the urgent care and specialty pharmacy markets amid growing demand for expanded-access overdose reversal solutions. This regulatory milestone allows IMS to compete directly with established branded competitors to supply critical, life-saving medications at a time when accessibility in emergency settings is increasingly codified by state requirements.